Related Experiment Video
Updated: Jul 13, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
[Proteic profiling SELDI-TOF and breast cancer: clinical potential applications]
Anthony Gonçalves1, François Bertucci, Daniel Birnbaum
1Centre de Recherche en Cancérologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli-Calmettes (IPC) et Inserm UMR 599, Marseille, France. goncalvesa@marseille.fnclcc.fr
Abstract:
Significant advances in early diagnosis, prognostic markers, therapeutic response and toxic effect indicators, together with the identification of new potential drug targets, have improved the survival of patients with breast cancer. Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives.
